Vera Therapeutics Advances Atacicept for Potential FDA Accelerated Approval
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy VERA?
"The team at Vera Therapeutics is focused on execution as we advance atacicept toward potential FDA accelerated approval in IgAN," said Marshall Fordyce, Founder and CEO of Vera Therapeutics. "During the first quarter, we made meaningful progress across key pre-commercial activities, including in sales, marketing, market access, compliance, and commercial operations, to support a successful U.S. launch, pending regulatory approval. We are excited for atacicept to potentially be the first approved drug targeting both BAFF and APRIL in IgAN patients."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VERA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VERA
Wall Street analysts forecast VERA stock price to rise
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 35.880
Low
33.00
Averages
74.08
High
100.00
Current: 35.880
Low
33.00
Averages
74.08
High
100.00
About VERA
Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. It is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. It retains all global developmental and commercial rights to atacicept and MAU868.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vera Therapeutics Reports Q1 Financial Results
- Financial Performance: Vera Therapeutics reported a Q1 GAAP EPS of -$1.69, indicating significant challenges in profitability that could impact investor confidence and lead to stock price volatility.
- Cash Flow Situation: For the quarter ending March 31, 2026, net cash used in operating activities was $106.5 million, a substantial increase from $54.4 million in the same quarter of 2025, suggesting pressure on the company's financial management that may affect future investment capabilities.
- Market Reaction: Analysts downgraded the rating to Hold based on the reassessment of Atacicept's potential in treating IgAN, reflecting a cautious market sentiment regarding the company's product prospects, which may lead to decreased investor confidence in future growth.
- Industry Conference: Vera Therapeutics presented at the TD Cowen 46th Annual Health Care Conference, actively seeking to communicate with investors despite financial challenges, showcasing its ongoing efforts in the healthcare sector.
See More
Vera Therapeutics to Present at Bank of America Health Care Conference
- Conference Participation: Vera Therapeutics' management team will present at the Bank of America Securities Health Care Conference on May 13, 2026, at 4:20 PM in Las Vegas, aiming to enhance the company's visibility and credibility among investors through one-on-one meetings.
- Lead Product Candidate: The company's lead product candidate, atacicept, is a self-administered weekly subcutaneous injection designed to treat serious immunological diseases by blocking BAFF and APRIL, which is expected to change the standard of care for conditions like IgA nephropathy and lupus nephritis.
- Research and Development Potential: Vera is also evaluating the clinical significance of atacicept in additional autoimmune diseases, showcasing its potential applications across a wide range of B-cell-mediated diseases, thereby enhancing its competitive position in the market.
- Exclusive Licensing Agreement: The company holds an exclusive license agreement with Stanford University for the development of the next-generation fusion protein VT-109, which is anticipated to offer broad therapeutic potential for B-cell-related diseases, further solidifying its research foundation.
See More
Vera Therapeutics Grants Stock Awards to New Employees
- Stock Option Grant: On April 8, 2026, Vera Therapeutics granted 258,200 non-qualified stock options to 89 new employees at an exercise price of $40.33 per share, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in the biotechnology sector.
- Restricted Stock Units: The company also awarded 131,925 restricted stock units (RSUs) that will vest over four years, with the first vesting on May 20, 2026, reflecting the company's commitment to long-term contributions from new employees and helping to boost employee loyalty.
- Compliance with Incentive Plan: The awards comply with Nasdaq Listing Rule 5635(c)(4), demonstrating Vera Therapeutics' adherence to regulations and transparency in attracting new talent, which enhances investor confidence in corporate governance.
- R&D Strategic Context: Vera Therapeutics focuses on developing treatments for serious immunological diseases, particularly its lead product atacicept, which aims to change the standard of care for patients, and the addition of new employees is expected to accelerate the R&D process.
See More
Vera Therapeutics Grants Stock Awards to New Chief Legal Officer
- Stock Option Grant: On March 23, 2026, Vera Therapeutics granted 56,850 non-qualified stock options to new Chief Legal Officer Jane Wright-Mitchell, with an exercise price of $40.73 per share, reflecting the closing price that day, aimed at attracting and retaining key talent.
- Restricted Stock Units: The award also includes 42,403 restricted stock units (RSUs) vesting over four years, demonstrating the company's commitment to the new employee and her significance in future business development.
- Vesting Arrangement: Both the stock options and RSUs are contingent on the new employee's continued service, ensuring long-term contributions to the company, reflecting Vera Therapeutics' emphasis on talent stability.
- Strategic Development Focus: Vera Therapeutics is dedicated to developing treatments for serious immunological diseases, particularly its lead product atacicept, which aims to change the standard of care for patients, showcasing the company's strategic foresight in the biotechnology sector.
See More
Vera Therapeutics Appoints New Chief Legal Officer
- Executive Appointment: Vera Therapeutics has appointed Jane Wright-Mitchell as Chief Legal Officer, effective immediately, bringing extensive experience in regulatory approvals, commercialization, and intellectual property management, which will support the company as it approaches the launch of its first-in-class dual BAFF/APRIL inhibitor.
- Enhanced Legal Support: With over 25 years of legal experience in the life sciences sector, including her role as General Counsel at Vaxcyte, Wright-Mitchell's expertise is expected to strengthen Vera's legal capabilities through key milestones and the potential commercial launch of atacicept.
- Product Development Outlook: Vera's lead product candidate, atacicept, aims to treat IgA nephropathy as a subcutaneous injection administered weekly, which is anticipated to change the standard of care for patients and further enhance the company's market position in immunological diseases.
- Strategic Collaboration and Innovation: Vera Therapeutics has secured an exclusive licensing agreement with Stanford University for the development of a next-generation fusion protein targeting BAFF and APRIL, known as VT-109, showcasing the company's broad potential in treating B-cell-mediated diseases.
See More
Kynam Capital Management Cuts Viridian Stake by Over $81 Million
- Stake Reduction: Kynam Capital Management sold 2,957,386 shares of Viridian Therapeutics in Q4 2026, with an estimated transaction value of $81.11 million, indicating a cautious outlook on the company's future performance.
- Holding Proportion Change: Following this transaction, Kynam's stake in Viridian decreased to 2.92%, reflecting a reassessment of asset allocation in its 13F report, which may impact investor confidence in the company.
- Market Performance: Viridian's stock price has surged 76% over the past year, currently priced at $26.98, significantly outperforming the S&P 500's roughly 15% gain, indicating strong market demand for its biotech products.
- R&D Expenditure: Despite facing nearly $339 million in R&D costs and an annual net loss of about $343 million, Viridian's cash reserves of approximately $875 million at year-end provide a financial cushion for future clinical trials and product launches.
See More
Vera Therapeutics Reports Q1 Financial Results
- Financial Performance: Vera Therapeutics reported a Q1 GAAP EPS of -$1.69, indicating significant challenges in profitability that could impact investor confidence and lead to stock price volatility.
- Cash Flow Situation: For the quarter ending March 31, 2026, net cash used in operating activities was $106.5 million, a substantial increase from $54.4 million in the same quarter of 2025, suggesting pressure on the company's financial management that may affect future investment capabilities.
- Market Reaction: Analysts downgraded the rating to Hold based on the reassessment of Atacicept's potential in treating IgAN, reflecting a cautious market sentiment regarding the company's product prospects, which may lead to decreased investor confidence in future growth.
- Industry Conference: Vera Therapeutics presented at the TD Cowen 46th Annual Health Care Conference, actively seeking to communicate with investors despite financial challenges, showcasing its ongoing efforts in the healthcare sector.
See More
Vera Therapeutics to Present at Bank of America Health Care Conference
- Conference Participation: Vera Therapeutics' management team will present at the Bank of America Securities Health Care Conference on May 13, 2026, at 4:20 PM in Las Vegas, aiming to enhance the company's visibility and credibility among investors through one-on-one meetings.
- Lead Product Candidate: The company's lead product candidate, atacicept, is a self-administered weekly subcutaneous injection designed to treat serious immunological diseases by blocking BAFF and APRIL, which is expected to change the standard of care for conditions like IgA nephropathy and lupus nephritis.
- Research and Development Potential: Vera is also evaluating the clinical significance of atacicept in additional autoimmune diseases, showcasing its potential applications across a wide range of B-cell-mediated diseases, thereby enhancing its competitive position in the market.
- Exclusive Licensing Agreement: The company holds an exclusive license agreement with Stanford University for the development of the next-generation fusion protein VT-109, which is anticipated to offer broad therapeutic potential for B-cell-related diseases, further solidifying its research foundation.
See More
Vera Therapeutics Grants Stock Awards to New Employees
- Stock Option Grant: On April 8, 2026, Vera Therapeutics granted 258,200 non-qualified stock options to 89 new employees at an exercise price of $40.33 per share, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in the biotechnology sector.
- Restricted Stock Units: The company also awarded 131,925 restricted stock units (RSUs) that will vest over four years, with the first vesting on May 20, 2026, reflecting the company's commitment to long-term contributions from new employees and helping to boost employee loyalty.
- Compliance with Incentive Plan: The awards comply with Nasdaq Listing Rule 5635(c)(4), demonstrating Vera Therapeutics' adherence to regulations and transparency in attracting new talent, which enhances investor confidence in corporate governance.
- R&D Strategic Context: Vera Therapeutics focuses on developing treatments for serious immunological diseases, particularly its lead product atacicept, which aims to change the standard of care for patients, and the addition of new employees is expected to accelerate the R&D process.
See More
Vera Therapeutics Grants Stock Awards to New Chief Legal Officer
- Stock Option Grant: On March 23, 2026, Vera Therapeutics granted 56,850 non-qualified stock options to new Chief Legal Officer Jane Wright-Mitchell, with an exercise price of $40.73 per share, reflecting the closing price that day, aimed at attracting and retaining key talent.
- Restricted Stock Units: The award also includes 42,403 restricted stock units (RSUs) vesting over four years, demonstrating the company's commitment to the new employee and her significance in future business development.
- Vesting Arrangement: Both the stock options and RSUs are contingent on the new employee's continued service, ensuring long-term contributions to the company, reflecting Vera Therapeutics' emphasis on talent stability.
- Strategic Development Focus: Vera Therapeutics is dedicated to developing treatments for serious immunological diseases, particularly its lead product atacicept, which aims to change the standard of care for patients, showcasing the company's strategic foresight in the biotechnology sector.
See More
Vera Therapeutics Appoints New Chief Legal Officer
- Executive Appointment: Vera Therapeutics has appointed Jane Wright-Mitchell as Chief Legal Officer, effective immediately, bringing extensive experience in regulatory approvals, commercialization, and intellectual property management, which will support the company as it approaches the launch of its first-in-class dual BAFF/APRIL inhibitor.
- Enhanced Legal Support: With over 25 years of legal experience in the life sciences sector, including her role as General Counsel at Vaxcyte, Wright-Mitchell's expertise is expected to strengthen Vera's legal capabilities through key milestones and the potential commercial launch of atacicept.
- Product Development Outlook: Vera's lead product candidate, atacicept, aims to treat IgA nephropathy as a subcutaneous injection administered weekly, which is anticipated to change the standard of care for patients and further enhance the company's market position in immunological diseases.
- Strategic Collaboration and Innovation: Vera Therapeutics has secured an exclusive licensing agreement with Stanford University for the development of a next-generation fusion protein targeting BAFF and APRIL, known as VT-109, showcasing the company's broad potential in treating B-cell-mediated diseases.
See More
Kynam Capital Management Cuts Viridian Stake by Over $81 Million
- Stake Reduction: Kynam Capital Management sold 2,957,386 shares of Viridian Therapeutics in Q4 2026, with an estimated transaction value of $81.11 million, indicating a cautious outlook on the company's future performance.
- Holding Proportion Change: Following this transaction, Kynam's stake in Viridian decreased to 2.92%, reflecting a reassessment of asset allocation in its 13F report, which may impact investor confidence in the company.
- Market Performance: Viridian's stock price has surged 76% over the past year, currently priced at $26.98, significantly outperforming the S&P 500's roughly 15% gain, indicating strong market demand for its biotech products.
- R&D Expenditure: Despite facing nearly $339 million in R&D costs and an annual net loss of about $343 million, Viridian's cash reserves of approximately $875 million at year-end provide a financial cushion for future clinical trials and product launches.
See More
